Olema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Olema Pharmaceuticals (NASDAQ:OLMA) in a report issued on Thursday, MarketBeat.com reports. The firm issued a buy rating and a $40.00 target price on the stock.

Several other analysts also recently issued reports on OLMA. UBS Group assumed coverage on Olema Pharmaceuticals in a report on Wednesday, January 7th. They issued a “buy” rating and a $45.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. The Goldman Sachs Group decreased their target price on Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday. Guggenheim dropped their target price on Olema Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Citigroup boosted their price target on Olema Pharmaceuticals from $60.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.40.

Olema Pharmaceuticals Trading Up 2.7%

Shares of OLMA stock opened at $14.96 on Thursday. The company has a quick ratio of 8.03, a current ratio of 9.95 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals has a fifty-two week low of $2.86 and a fifty-two week high of $36.26. The firm’s 50 day moving average price is $23.35 and its two-hundred day moving average price is $18.67. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -8.04 and a beta of 1.92.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.01. On average, analysts anticipate that Olema Pharmaceuticals will post -2.33 EPS for the current year.

Insider Activity at Olema Pharmaceuticals

In related news, insider David C. Myles sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $27.60, for a total transaction of $1,380,000.00. Following the sale, the insider directly owned 542,761 shares of the company’s stock, valued at approximately $14,980,203.60. This represents a 8.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Naseem Zojwalla sold 100,000 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $28.04, for a total value of $2,804,000.00. Following the transaction, the insider owned 53,997 shares in the company, valued at $1,514,075.88. This trade represents a 64.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 419,701 shares of company stock worth $11,603,868 over the last quarter. 16.36% of the stock is owned by corporate insiders.

Institutional Trading of Olema Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in OLMA. Virtu Financial LLC bought a new position in shares of Olema Pharmaceuticals in the 4th quarter worth about $1,061,000. Invesco Ltd. grew its position in shares of Olema Pharmaceuticals by 25.0% during the 4th quarter. Invesco Ltd. now owns 155,732 shares of the company’s stock valued at $3,893,000 after buying an additional 31,098 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in Olema Pharmaceuticals during the fourth quarter worth about $250,000. Vestal Point Capital LP acquired a new stake in shares of Olema Pharmaceuticals during the 4th quarter worth approximately $41,250,000. Finally, Wellington Management Group LLP raised its position in shares of Olema Pharmaceuticals by 8.2% during the 4th quarter. Wellington Management Group LLP now owns 220,971 shares of the company’s stock worth $5,524,000 after purchasing an additional 16,764 shares during the period. Institutional investors own 91.78% of the company’s stock.

Trending Headlines about Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Jefferies initiated coverage with a “Buy” and $40 price target (large upside vs. current levels), giving fresh institutional endorsement that can attract buyers. Jefferies Initiates Coverage – Benzinga
• Positive Sentiment: JPMorgan raised its price target to $58 and kept an “Overweight” stance — a high-profile upward revision that can drive momentum and re-rate expectations. JPMorgan Raises Price Target – Benzinga
• Positive Sentiment: HC Wainwright lifted EPS estimates across 2026–2030 and reiterated a “Buy” with a $38 target, signaling analyst confidence in improving fundamentals over the medium term. HC Wainwright Estimate Raises – MarketBeat
• Positive Sentiment: Olema reported better‑than‑expected quarterly results this week, which, along with raised analyst outlooks, is a near‑term bullish catalyst supporting the stock. Earnings Beat Drives Stock – AmericanBankingNews
• Positive Sentiment: Upcoming/preclinical data (palazestrant and OP‑3136) to be presented at AACR and a large reported $68.7M investor bet on a 2027 breast‑cancer launch are potential medium‑term catalysts for upside if data or investor interest validates the story. AACR Presentation – BusinessInsider Large Bet Report – The Globe and Mail
• Neutral Sentiment: Zacks notes the stock has been heavily sold (down ~33% over 4 weeks) and is technically oversold; that increases the chance of a short‑term bounce but also underscores elevated downside risk if catalysts disappoint. Oversold / Technical Note – Zacks
• Negative Sentiment: Guggenheim published a pessimistic forecast and an analyst downgrade hit headlines, pressuring the stock intraday — a reminder that not all desks are aligned with the recent bullish notes. Guggenheim Pessimistic Forecast – AmericanBankingNews
• Negative Sentiment: AmericanBankingNews reported an analyst downgrade that coincided with a notable intra‑day pullback, illustrating how mixed analyst views are fueling volatility. Analyst Downgrade / Price Reaction – AmericanBankingNews
• Negative Sentiment: Goldman Sachs trimmed its price target from $38 to $27 (while keeping a “Buy”), which reduces the consensus upside and may cap near‑term rallies until data or execution de‑risk the story. Goldman Lowers Target – Benzinga

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.